-+ 0.00%
-+ 0.00%
-+ 0.00%

Goldman Sachs Reinstates Neutral on Arrowhead Pharma, Announces $74 Price Target

Benzinga·09/24/2026 11:53:01
Goldman Sachs analyst Andrea Newkirk reinstates Arrowhead Pharma (NASDAQ:ARWR) with a Neutral and announces $74 price target.